Precedex

Precedex is a brand name of dexmedetomidine, approved by the FDA in the following formulation(s):

PRECEDEX (dexmedetomidine hydrochloride - injectable; injection)

• 
  Manufacturer: HOSPIRA
  
  Approval date: December 17, 1999
  
  Strength(s): EQ 100MCG BASE/ML (EQ100MCG BASE/ML) ^[RLD]

Has a generic version of Precedex been approved?

No. There is currently no therapeutically equivalent version of Precedex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Precedex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist
  Patent 4,910,214
  Issued: March 20, 1990
  Inventor(s): Karjalainen; Arto J. & Virtanen; Raimo E. & Savolainen; Eino J.
  Assignee(s): Farmos Yhtyma Oy
  The separated d and l enantiomers of medetomidine and their salts are selective and potent .alpha..sub.2 -receptor agonists.
  
  Patent expiration dates:
  
  
  • July 15, 2013
    
    ✓ 
    Patent use: USE FOR SEDATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  4-substituted imidazole derivatives useful in perioperative care
  Patent 5,344,840
  Issued: September 6, 1994
  Inventor(s): Maze; Mervyn & Scheinin; Mika
  Assignee(s): Orion-Yhtyma OY
  4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, known as medetomidine, and in particular its d-enantiomer and salts thereof are useful in perioperative care, in particular in reducing the amount of anaesthetic it is necessary to administer.
  
  Patent expiration dates:
  
  
  • September 6, 2011
    
    ✓ 
    Patent use: SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
  
  



• 
  Use of dexmedetomidine for ICU sedation
  Patent 6,716,867
  Issued: April 6, 2004
  Inventor(s): Riku; Aantaa & Romeo; Bachand & Esa; Heinonen
  Assignee(s): Orion Corporation
  The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
  
  Patent expiration dates:
  
  
  • March 31, 2019
    
    ✓ 
    Patent use: INTENSIVE CARE UNIT SEDATION
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 17, 2011 - SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCUDURES
  
  

See also...

• Precedex AHFS DI Monographs (ASHP)
• Dexmedetomidine Hydrochloride AHFS DI Monographs (ASHP)